Colucci Norman
Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Friday, April 4, 2008

Report: IlluminOss takes on $11M in round two funding

IlluminOss Medical Inc. has raised $11.02 million in Series B funding, according to published reports.

IlluminOss Medical, which is based in East Providence, R.I., develops medical devices for the treatment of bone fractures.

Investors included New Leaf Ventures, a venture capital firm with operations in New York City and California, and Rowayton, Conn.-based Foundation Medical Partners, according to the website PE Hub.

Last year, IlluminOss Medical reportedly closed on $925,000 of a $2.68 million Series A financing round led by Foundation Medical Partners.

IlluminOss CEO Robert Rabiner previously held CEO roles of Wilmington-based OmniSonics Medical Technologies Inc. and Selva Medical Inc., a medical device company previously located in Belmont, Calif.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Despite World Series, local algorithm helps jobless New Yorkers

NPR's Morning Edition reports on job counseling efforts at the state of New York's Department of Labor, and finds it's using an algorithm developed by Burning Glass Technologies, which is based in Quincy Market. Burning Glass develops algorithms that parse resume information and try to match job seekers with companies that will actually hire them. The job seeker in the story, a publishing i...

Read More

Boston University - MS MBA
Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio